High uptake of HIV testing when self-tests are offered to outpatients in Malawi
Unprecedented hepatitis C infection rates seen in gay men in Amsterdam PrEP programme
Dolutegravir dual therapy works well for first-time HIV treatment
PrEP does not lower feminising hormone level in transgender women
Rapid treatment initiation and less time with detectable HIV linked to falls in new HIV diagnoses in San Francisco and Melbourne
Dolutegravir: update on infant neural tube defects from Botswana
Criminalisation of HIV high on agenda at AIDS 2018
Dolutegravir-based ART recommended for all – if reliable contraception is available
Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment
On-demand dosing as effective as daily dosing in first year of French PrEP study
Zero transmissions mean zero risk – PARTNER 2 study results announced
The “Undetectable = Untransmittable” message goes global: I=I, N=N and B=B
Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?
